Coventry, UK, 12th June 2017 / Sciad Newswire / Medherant Ltd, a University of Warwick spin-out company developing a novel transdermal drug delivery patch technology, has been chosen as one of 40 companies shortlisted for the Royal Society of Chemistry (RSC) Emerging Technologies Competition 2017.
Medherant has been selected for its versatile and easy to use, solvent-free, transdermal drug delivery platform, the TEPI Patch®, which is based upon a novel poly(ether-urethane)/silicone pressure sensitive adhesive that allows a wider range of drugs to be delivered across the skin. The Company has also created a novel high-throughput analytical system to facilitate the rapid development of its own and third party TEPI Patches.
Nigel Davis, CEO of Medherant, commented, “We are delighted to have been shortlisted for this prestigious competition. Recognition of our technology from the RSC is further evidence of the innovative nature of our TEPI Patch® technology and the progress we’ve made towards developing a product that will be easier for patients to use.”
Shortlisted entrants will pitch their ideas to a panel of experts in front of a live audience at the RSC’s annual flagship event for industry, Chemistry Means Business. This event will be held in Manchester, UK on the 13th and 14th June 2017, where a winner will be selected. Dr Gabit Nurumbetov, a senior scientist at Medherant, will also be presenting the TEPI Patch® technology at this event.
Nicola Broughton, Head of Universities at Mercia Technologies PLC, which invested in Medherant last year, said, “It’s fantastic to see Medherant’s innovative TEPI Patch® technology recognised in the RSC competition. It offers huge potential benefits for patients in need of an alternative way of receiving their medication. Mercia is pleased to support the Medherant team as it continues to grow and scale its business.”
For further information, contact:
Nigel Davis, CEO
T: +44 (0)24 7632 3060
Media Relations, Sciad Communications
Deborah Cockerill, Managing Partner
T: +44 (0)20 7470 8801
Notes for Editors
Medherant Ltd is a leading developer of next-generation transdermal drug delivery patches. The Company was founded by Professor David Haddleton and the University of Warwick in 2015.
Medherant has built upon its founders’ world-leading expertise in bio-adhesives and polymer chemistry to create adhesive drug delivery patches that overcome many of the limitations of patches currently on the market:
- Its TEPI Patch® technology can be used with a wider range of drugs, including those that are not suitable for oral administration.
- The amount of drug that can be loaded into the patch is greater, enabling the development of more effective transdermal therapies.
- The TEPI Patch® contains a novel adhesive which will provide a better patient experience as the patch sticks to the skin for longer, is less painful to remove, and does not leave a mark on the skin.
Medherant is developing products containing proven drugs that it intends to license prior to commercialisation. The Company’s first product is an ibuprofen patch. Manufacture for clinical trials will take place at AdhexPharma in France in the second half of 2017.
Medherant also runs feasibility studies that give companies the opportunity to see the benefits of delivering their drugs with TEPI Patch® technology. Medherant seeks partnerships with companies wishing to extend the commercial life of their products or those that have drugs that cannot be delivered orally at sufficient dosage.
Medherant is backed by Mercia Technologies PLC, a national investment group focused on the creation, funding and scaling of innovative businesses with high growth potential from the UK regions.
For more information, please see www.medherant.co.uk